Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Affects approximately 5-8% of the global adult population. 14.5 million people in the US (NSDUH 2019). Leading cause of preventable death. Only about 7.5% of patients receive any treatment.
Behavioral therapies (CBT, motivational interviewing, 12-step), pharmacotherapy (naltrexone, acamprosate, disulfiram). 1-year relapse rates remain around 40-60% even with optimal treatment.
Psilocybin-assisted therapy has shown promise in reducing heavy drinking. The mechanism may involve disrupting entrenched neural patterns of addictive behavior and enhancing motivation for change through insights gained during the psychedelic experience.
Bogenschutz et al. (2022): Psilocybin significantly reduced percentage of heavy drinking days vs. active placebo in RCT. Meta-analysis of 1960s LSD trials (Krebs & Johansen, 2012) showed significant benefit for alcohol misuse.